Physician profile
Syed Kamil Ali Zaidi
NPI 1225242647
$5,455.06
in general payments reported to CMS, 2019-2025
21 companies · $2,855 in 2025
The $2,855 reported for 2025 was more than what 94% of Addiction Psychiatry providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $463 · 2023: $909 · 2024: $1,228 · 2025: $2,855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,992.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $905.65 | 2023-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $754.07 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $658.31 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $492.77 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $453.75 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $439.84 | 2023-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $398.22 | 2022-2025 | Spravato, Invega Sustenna, Invega |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $366.43 | 2024-2025 | Caplyta |
| Indivior INC. | $308.47 | 2022-2025 | Sublocade, Perseris |
| E.R. Squibb & Sons, L.L.C. | $235.68 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $119.60 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $112.04 | 2022-2023 | Quviviq |
| Lilly USA, LLC | $34.83 | 2025 | Zepbound |
| Tms Neurohealth Centers INC. | $33.82 | 2025 | Tms Neurohealth Centers INC. |
| Takeda Pharmaceuticals U.S.A., INC. | $29.70 | 2025 | Trintellix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.95 | 2025 | Rexulti |
| Almatica Pharma LLC | $21.89 | 2025 | Loreev Xr |
| Alnylam Pharmaceuticals INC. | $19.75 | 2024 | Givlaari |
| Axsome Therapeutics, INC. | $17.95 | 2023 | Auvelity |
| Neos Therapeutics, Lp | $15.38 | 2024 | Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Zaidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.